SCHEMBL1843699

SCHEMBL1843699

CCCCCCCCCCCCCCCCCCOC(CC(=O)O)(CC(=O)O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.42
BLM P54132 1/20 0.42
HSPE1 P61604 1/20 0.42
GPR84 Q9NQS5 7/20 0.42
PPARG P37231 7/20 0.42
PPARD Q03181 7/20 0.42
PPARA Q07869 7/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
PTPN1 P18031 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
MEN1 O00255 1/20 0.42
ESR1 P03372 1/20 0.42
ALOX15 P16050 1/20 0.42
PDE4A P27815 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9809582 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL9513723 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL2488203 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL8507314 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL9513981 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL8505820 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL3223653 1.00 HSPD1 (0.42) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL9516379 0.98 HSPD1 (0.41) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL9724549 0.98 HSPD1 (0.41) HSPD1BLMHSPE1GPR84PPARG
SCHEMBL9513925 0.98 HSPD1 (0.41) HSPD1BLMHSPE1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8568808-B2 Intercalated layered silicate CRYOVAC, INC. (US) 2013-10-29 US disclosed
WO-2012177703-A1 IMPACT-MODIFIED POLYPROPYLENE COMPOSITE CRYOVAC, INC. (US) 2012-12-27 WO disclosed
US-20120328754-A1 Impact-Modified Polypropylene Composite CRYOVAC, INC. (US) 2012-12-27 US disclosed
EP-1833902-B1 INTERCALATED LAYERED SILICATE CRYOVAC INC (US) 2011-05-18 EP disclosed
US-20100040653-A1 Intercalated layered silicate CRYOVAC, INC. 2010-02-18 US disclosed
EP-1833902-A1 INTERCALATED LAYERED SILICATE Cryovac, Inc. (US) 2007-09-19 EP disclosed
US-20060122309-A1 Intercalated layered silicate CRYOVAC, INC. 2006-06-08 US disclosed
WO-2006060716-A1 INTERCALATED LAYERED SILICATE CRYOVAC, INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040653-A1 Intercalated layered silicate SMC4, SMC1A, SMCHD1 HSPD1 1762/4885BLM 129/4885HSPE1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.